
NHI Stock Forecast & Price Target
NHI Analyst Ratings
Bulls say
National Health Investors is a well-established healthcare REIT with a diverse portfolio of high-quality properties in the senior housing and medical facilities sector. It has a strong financial position with low leverage and a solid investment pipeline, which supports future growth potential. Its recent decision to sell its entire portfolio to National HealthCare Corporation (NHC), rather than just resetting rents, shows a long-term vision for organic growth and resolves any potential conflicts of interest. However, there are some risks, such as underperforming NHC rent reset or weaker deferred rent collection, that could affect the company's performance. Additionally, an increase in government reimbursement disruptions or higher national supply in the senior housing market could impact the company's stock performance and the achievement of its consensus price target. Overall, the stock is currently trading at a premium to its outlook, but with its strong portfolio and growth potential, it remains a solid investment for those with a longer-term perspective.
Bears say
National Health Investors is facing a negative outlook due to the sale of its portfolio to current lessee National HealthCare Corporation (NHC) for $560 million, resulting in a reduced FFO estimate for 2026 and 2027. While the decision to sell may improve long-term growth for the company, it also presents a potential loss of revenue and potential competition from a third party bidder. NHI has a high dependence on top operators which can add risk. Alternatively, NHI has high dependence on its top few operators, which can be good (given the struggles many weaker operators are having) or bad (even good operators can run intodifficulties).
This aggregate rating is based on analysts' research of National Health Investors and is not a guaranteed prediction by Public.com or investment advice.
NHI Analyst Forecast & Price Prediction
Start investing in NHI
Order type
Buy in
Order amount
Est. shares
0 shares